ORIC PHARMACEUTICALS, INC. Depreciation
ORIC PHARMACEUTICALS, INC. (ORIC) reported Depreciation of $534.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. depreciation for the quarter ending 2026-06-30 was $264.00K, a 14.84% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. depreciation for the quarter ending 2026-03-31 was $270.00K, a 10.60% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. depreciation for the quarter ending 2025-12-31 was $320.00K, a 5.26% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. depreciation for the quarter ending 2025-09-30 was $288.00K, a 6.67% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. depreciation for fiscal 2025 was $1.22M, a 10.21% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. depreciation for fiscal 2024 was $1.11M, a 7.27% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. depreciation for fiscal 2023 was $1.03M, a 6.83% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. depreciation for fiscal 2022 was $966.00K, a 7.69% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $534.00K 10-Q · filed 2026-08-03 | $854.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.14M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $270.00K 10-Q · filed 2026-05-04 | $590.00K derived: sum of 2 quarters · filed 2026-05-04 | $878.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $608.00K derived: sum of 2 quarters · filed 2026-02-23 | $918.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.22M 10-K · filed 2026-02-23 |
| 2025-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $598.00K derived: sum of 2 quarters · filed 2026-08-03 | $900.00K 10-Q · filed 2025-11-13 | $1.20M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $310.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $612.00K 10-Q · filed 2026-08-03 | $916.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $302.00K 10-Q · filed 2026-05-04 | $606.00K derived: sum of 2 quarters · filed 2026-05-04 | $876.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.15M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $574.00K derived: sum of 2 quarters · filed 2026-02-23 | $846.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.11M 10-K · filed 2026-02-23 |
| 2024-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $542.00K derived: sum of 2 quarters · filed 2025-11-13 | $803.00K 10-Q · filed 2025-11-13 | $1.07M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $272.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $533.00K 10-Q · filed 2025-08-12 | $796.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.05M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $261.00K 10-Q · filed 2025-05-05 | $524.00K derived: sum of 2 quarters · filed 2025-05-05 | $781.00K derived: sum of 3 quarters · filed 2025-05-05 | $1.04M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $520.00K derived: sum of 2 quarters · filed 2025-02-18 | $779.00K derived: sum of 3 quarters · filed 2025-02-18 | $1.03M 10-K · filed 2025-02-18 |
| 2023-09-30 | $257.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $516.00K derived: sum of 2 quarters · filed 2024-11-12 | $769.00K 10-Q · filed 2024-11-12 | $1.02M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $512.00K 10-Q · filed 2024-08-12 | $759.00K derived: sum of 3 quarters · filed 2024-08-12 | $980.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $253.00K 10-Q · filed 2024-05-06 | $500.00K derived: sum of 2 quarters · filed 2024-05-06 | $721.00K derived: sum of 3 quarters · filed 2024-05-06 | $968.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $468.00K derived: sum of 2 quarters · filed 2024-03-11 | $715.00K derived: sum of 3 quarters · filed 2024-03-11 | $966.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $468.00K derived: sum of 2 quarters · filed 2023-11-06 | $719.00K 10-Q · filed 2023-11-06 | $948.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $247.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $498.00K 10-Q · filed 2023-08-10 | $727.00K derived: sum of 3 quarters · filed 2023-08-10 | $944.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $251.00K 10-Q · filed 2023-05-08 | $480.00K derived: sum of 2 quarters · filed 2023-05-08 | $697.00K derived: sum of 3 quarters · filed 2023-05-08 | $919.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $446.00K derived: sum of 2 quarters · filed 2023-03-16 | $668.00K derived: sum of 3 quarters · filed 2023-03-16 | $897.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $439.00K derived: sum of 2 quarters · filed 2022-11-07 | $668.00K 10-Q · filed 2022-11-07 | $902.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $222.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $451.00K 10-Q · filed 2022-08-11 | $685.00K derived: sum of 3 quarters · filed 2022-08-11 | $925.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $229.00K 10-Q · filed 2022-05-09 | $463.00K derived: sum of 2 quarters · filed 2022-05-09 | $703.00K derived: sum of 3 quarters · filed 2022-05-09 | $949.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $474.00K derived: sum of 2 quarters · filed 2022-03-21 | $720.00K derived: sum of 3 quarters · filed 2022-03-21 | $970.00K 10-K · filed 2022-03-21 |
| 2020-09-30 | $240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $486.00K derived: sum of 2 quarters · filed 2021-11-08 | $736.00K 10-Q · filed 2021-11-08 | $1.01M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-06-30 | $246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $496.00K 10-Q · filed 2021-08-10 | $766.00K derived: sum of 3 quarters · filed 2022-03-21 | $1.04M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-03-31 | $250.00K 10-Q · filed 2021-05-06 | $520.00K derived: sum of 2 quarters · filed 2022-03-21 | $790.00K derived: sum of 3 quarters · filed 2022-03-21 | $1.04M derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $540.00K derived: sum of 2 quarters · filed 2022-03-21 | $786.00K derived: sum of 3 quarters · filed 2022-03-21 | $1.03M 10-K · filed 2022-03-21 |
| 2019-09-30 | $270.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $516.00K derived: sum of 2 quarters · filed 2020-11-05 | $758.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $488.00K 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $242.00K 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | $903.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |